Mushrooms vs. Anti-Anxiety Meds: Natural Alternatives?

Functional Mushrooms for Anxiety

33.5% anxiety reduction (HAM-A)

A 2026 double-blind, placebo-controlled trial (n=50) found that a five-mushroom blend reduced Hamilton Anxiety (HAM-A) scores by 33.5% over 12 weeks, versus 13.1% in the placebo group (p=0.002). This is the strongest controlled human data to date for functional mushrooms and anxiety.

Hisamuddin et al., Brain and Behavior, 2026

OR 0.31

adjusted odds of depression in the middle tertile of mushroom intake vs. the lowest, among 24,699 NHANES participants — but no dose-response (Ba et al., 2021)

5 RCTs

randomized controlled trials of Lion's Mane as a supplement, included in the 2025 Menon systematic review

Not FDA-approved

functional mushrooms are sold as supplements, not as medications approved for treating anxiety disorders

Hisamuddin et al., Brain and Behavior, 2026

View as image ↗

The question of mushrooms vs. anti-anxiety medications is increasingly common. People already taking benzodiazepines or SSRIs want to know whether functional mushrooms are a viable alternative, a useful adjunct, or a combination to be careful about. The most recent controlled trial puts a number on what mushrooms can do: on the Hamilton Anxiety Scale, a five-mushroom blend reduced anxiety scores by 33.5% over 12 weeks, compared to 13.1% in the placebo group (p=0.002).^[1]

That's a meaningful, statistically robust result. It's also from one small trial of a multi-mushroom blend, not a head-to-head comparison against a prescription medication. Understanding what the research actually shows, where it falls short, and what the drug interaction landscape looks like when mushrooms are combined with existing anxiety medications requires more than a single headline number. This article covers all three. For the broader picture of adaptogenic mushrooms and stress, see Adaptogenic Mushrooms for Stress: How They Help Your Body Cope.

What the 2026 Trial Actually Showed

In 2026, Hisamuddin and colleagues published a randomized, double-blind, placebo-controlled trial in Brain and Behavior testing an adaptogenic mushroom blend on stress, fatigue, and sleep.^[1] Fifty participants were randomized to the blend (a proprietary product, "Restake," combining Lion's Mane, Cordyceps militaris, Reishi, Shiitake, and Maitake) or placebo for 12 weeks. Anxiety was measured on two validated scales: the Hamilton Anxiety Scale (HAM-A) and the State-Trait Anxiety Inventory (STAI-S).

The mushroom group improved significantly more than placebo on both. On HAM-A, anxiety fell 33.5% versus 13.1% in the placebo group at 12 weeks (p=0.002); on STAI-S state anxiety, it fell 8.7% versus 4.9% (p=0.011). Depression (BDI), fatigue, and sleep quality (PSQI) also improved significantly, and serum cortisol, ACTH, and CRP all decreased.

Strongest controlled human data

Hisamuddin et al. (2026) · Brain and Behavior

Population

50 adults (25 per group) experiencing stress and fatigue — not a diagnosed anxiety-disorder population

Intervention

A five-mushroom blend ('Restake': Lion's Mane, Cordyceps, Reishi, Shiitake, Maitake) for 12 weeks

Comparator

Placebo, double-blind

Finding

Anxiety fell significantly more in the mushroom group: Hamilton Anxiety (HAM-A) −33.5% vs. −13.1% for placebo (p=0.002), and state anxiety (STAI-S) −8.7% vs. −4.9% (p=0.011). Depression, fatigue, and sleep scores also improved, alongside lower cortisol, ACTH, and CRP.

positive Small (n=50), a multi-species blend rather than any single mushroom, and in a stressed but non-diagnosed population — not a head-to-head test against medication.

Hisamuddin et al., Brain and Behavior, 2026

The result is real, it comes from a controlled design, and it's the strongest human trial data currently published for functional mushrooms in anxiety. It's worth being precise about what it is not. The study tested a combination of five species, not any single mushroom, so it cannot tell you which component drove the effect; the blend's specific formula, dose, and extract standardization matter for replication and vary across products. The trial measured anxiety scores on validated scales, not clinical outcomes like medication dose changes or hospitalization avoidance. And the population was adults experiencing stress and fatigue, not people diagnosed with generalized anxiety disorder or panic disorder.

None of these qualifications erases the finding, but they do mean the 2026 result can't be directly compared to the efficacy data for lorazepam or escitalopram, which were tested in specifically diagnosed populations over far longer histories of research.

How Anti-Anxiety Medications Work (and Why People Look for Alternatives)

Prescription anxiety medications fall into two main categories with very different mechanisms, timescales, and risk profiles.

Benzodiazepines (like diazepam, lorazepam, and alprazolam) enhance the activity of GABA (gamma-aminobutyric acid), the brain's primary inhibitory neurotransmitter. GABA calms neural firing; benzodiazepines amplify GABA's effect by making GABA receptors more sensitive. The result is rapid anxiety reduction that can occur within 30-60 minutes. The tradeoff is significant: benzodiazepines produce physical dependence with regular use, carry withdrawal risks that can be medically serious, cause cognitive impairment and sedation, and lose effectiveness as tolerance develops.

SSRIs and SNRIs (like sertraline, escitalopram, and venlafaxine) work through a different mechanism, increasing the availability of serotonin (and in SNRIs, norepinephrine) at synapses by blocking their reuptake. SSRIs take 4-6 weeks to produce therapeutic effects, carry no addiction risk, and are generally well-tolerated, but produce side effects including nausea, sexual dysfunction, and initial anxiety worsening during the first few weeks of use. They are first-line pharmacological treatments for generalized anxiety disorder and panic disorder.

Why people look for alternatives is understandable given these profiles. Benzodiazepine dependence is a significant clinical problem, and SSRIs produce side effects that many people find difficult to tolerate. Functional mushrooms address the same desired outcome (less anxiety) through mechanisms that, on current evidence, produce neither dependence nor the common pharmaceutical side effects.

How Functional Mushrooms Approach Anxiety: Two Different Mechanisms

Functional mushrooms don't share a single anxiety-reduction mechanism. Reishi and lion's mane, the two species with the most clinical evidence, work through different pathways.

Reishi's pathway: GABAergic and HPA-axis modulation. The preclinical picture for reishi is genuinely mixed, which is worth stating plainly. Singh and colleagues in 2016 found that a methanol extract of Ganoderma lucidum (200 mg/kg) produced a significant anxiolytic effect in mice in the elevated plus maze, comparable to the standard drug diazepam (2 mg/kg), and reported anxiolytic activity across four different Ganoderma species, suggesting a genus-level property; the active fraction was rich in phenols and flavonoids.^[3] But not every reishi study finds an anxiolytic effect. Socala and colleagues in 2015 tested an aqueous extract of reishi mycelium and found antidepressant-like activity (reduced immobility in the forced swim test) and a raised psychomotor seizure threshold, but no anxiolytic or sedative effect in their model.^[2] These are preclinical, species- and extract-dependent findings; they establish plausible mechanisms, not human equivalence to diazepam. In a separate strand, Yao and colleagues found that a reishi mycelium extract promoted sleep in mice while raising hypothalamic serotonin (5-HT) and enriching gut bacteria such as Bifidobacterium, pointing to a gut-brain and serotonergic route.^[4]

In human trials, Mitra and colleagues conducted a 12-week RCT with female college students, finding that reishi supplementation significantly reduced psychological stress scores vs. placebo.^[5] Pazzi and colleagues tested reishi in women with fibromyalgia and saw trends toward improved mood and reduced depression, but the between-group differences did not reach statistical significance, and that population's disease-specific context limits how broadly the findings apply.^[6]

Lion's Mane's pathway: nerve growth factor and hippocampal neurogenesis. Lion's mane contains compounds (hericenones and erinacines) that stimulate the synthesis of nerve growth factor (NGF) and brain-derived neurotrophic factor (BDNF), proteins that support the survival and growth of neurons. NGF and BDNF are both implicated in depression and anxiety; compounds that restore them are a target of several drug development programs.

Nagano and colleagues conducted a double-blind RCT with 30 menopausal women over four weeks. Lion's mane supplementation significantly reduced depression (CES-D) and indefinite-complaints scores from baseline, and certain anxiety-related complaints separated from placebo.^[7] Vigna and colleagues ran an eight-week RCT with 77 overweight and obese adults, finding that lion's mane significantly improved depression, anxiety, and sleep scores vs. placebo; circulating pro-BDNF (the precursor) rose, although mature BDNF did not increase, making the biomarker signal genuinely mixed rather than a clean confirmation.^[8]

Surendran and colleagues published a 2025 acute, double-blind crossover study giving 18 healthy young adults a single 3 g dose of lion's mane fruiting-body extract.^[9] It is often cited as evidence of same-day mood benefit, but the study found no significant acute effect on composite measures of mood or global cognition; only an isolated psychomotor sub-test (the pegboard) improved at 90 minutes. It is an honest reminder that lion's mane's neurotrophic mechanism is presumed to require sustained supplementation, and that a single dose does not reliably shift mood.

For a dedicated deep-dive on lion's mane and anxiety, see Lion's Mane and Anxiety Reduction: Mechanisms and Studies. For reishi specifically, see Reishi for Anxiety: Clinical and Preclinical Evidence. For how reishi modulates the cortisol stress response, see How Mushrooms Regulate the HPA Axis and Cortisol.

The Population Signal: What 24,699 Americans Suggest About Mushrooms and Mood

Clinical trials test specific populations under controlled conditions. Population studies capture what actually happens when people choose to eat mushrooms in everyday life.

Ba and colleagues analyzed data from 24,699 participants in the National Health and Nutrition Examination Survey (NHANES), a nationally representative US health survey, covering the years 2005-2016.^[10] After adjusting for confounders, participants in the middle tertile of mushroom intake (median 4.9 g/day) had lower adjusted odds of depression than the lowest tertile (adjusted OR 0.31; 95% CI 0.16-0.60), where depression was defined as a PHQ-9 score of 10 or above. Crucially, the highest-intake tertile (median 19.6 g/day) showed no significant association (adjusted OR 0.91; 95% CI 0.47-1.78), and the trend across tertiles was not significant (P-trend 0.42).

This is an association, not evidence of causation, and the absence of a dose-response relationship weakens any simple "more mushrooms, less depression" reading. People who eat mushrooms may differ from non-consumers in many ways that weren't fully captured by statistical adjustment. Ba et al. propose bioactive compounds such as ergothioneine, an antioxidant found in edible mushrooms, as plausible mediators.

What the finding does establish is that mushroom consumption is associated with a population-level mood signal detectable across nearly 25,000 people, which makes the mechanistic research on specific species more plausible as a real-world phenomenon rather than a lab artifact — while stopping well short of proving that eating mushrooms lowers depression risk.

The Evidence Side by Side

The key observation from this comparison is not that mushrooms are better or worse than prescription medications. It's that they operate differently across every dimension. Speed, mechanism, risk profile, evidence base, and regulatory status are all distinct. These are not interchangeable options for the same need.

Evidence Review

1. Mechanistic / cell studiescompleted

   GABAergic and NGF/BDNF pathways characterized

2. Animal modelscompleted

   Anxiolytic (Singh 2016) and antidepressant-like (Socala 2015) effects; results extract-dependent

3. Small human RCTscurrent

   n=30-77 single-species trials plus the n=50 blend trial, in specific or non-diagnosed populations

4. Large anxiety-disorder RCTsmissing

   None in diagnosed generalized anxiety or panic disorder

5. Head-to-head vs. medicationmissing

   No trial compares mushrooms directly against a benzodiazepine or SSRI

Mechanistic and animal evidence is solid, and small human trials point in a consistent direction, but there is no large anxiety-disorder RCT and no head-to-head comparison against prescription medication.

Singh 2016; Socala 2015; Nagano 2010; Vigna 2019; Mitra 2024; Hisamuddin 2026; Cha 2024

The 2024 review by Cha and colleagues in Neuroscience and Biobehavioral Reviews concluded that mushroom consumption is associated with improved mood, reduced anxiety, and better cognitive outcomes across the lifespan, with the strongest evidence for lion's mane and reishi specifically.^[11] Cha et al. call for standardized dosing in future trials, reflecting the current limitation: even the positive trials use different doses, extract types, and populations, making it difficult to establish optimal protocols.

The Menon and colleagues 2025 systematic review, covering five RCTs of lion's mane as a supplement plus 15 laboratory studies and three pilot clinical trials, concluded that the overall evidence signal for cognitive function and mood is positive, with a favorable safety profile and rare adverse events.^[12]

Fact Check

Can functional mushrooms replace anxiety medication?

The claim

“Functional mushrooms are a proven natural replacement for prescription anxiety medication.”

Supplement marketing extrapolating from early, small, non-diagnostic trials

What research shows

Unsupported

No trial has compared mushrooms head-to-head against a benzodiazepine or SSRI, none is FDA-approved for anxiety, and the human evidence base is far smaller than for prescription drugs.

A real controlled signal does exist — the 2026 blend trial cut HAM-A anxiety 33.5% vs. 13.1% on placebo — and mushrooms carry a very different mechanism and risk profile. That makes them a different tool worth studying, not an established substitute.

Hisamuddin 2026; Menon 2025; Cha 2024 review

The honest summary: functional mushrooms are not at parity with decades of prescription medication trials. The data they have is real, consistent in direction, and growing rapidly. They represent a different tool with a different risk profile, not an equivalent substitute.

Drug Interactions: Taking Mushrooms Alongside Anxiety Medications

The drug interaction question is the safety-critical piece of this topic that almost no competitor covers. It matters because many people who are curious about mushrooms for anxiety are currently taking prescription medications.

Reishi raises a specific pharmacokinetic concern. Its triterpenoid compounds inhibit CYP3A4, a liver enzyme that metabolizes a large fraction of commonly prescribed drugs, including many benzodiazepines (midazolam, triazolam, alprazolam) and some SSRIs. If CYP3A4 is slowed by reishi triterpenoids, blood levels of these drugs could rise, potentially intensifying their effects or side effects. The evidence for this mechanism comes from in vitro and animal pharmacology; clinical interaction cases in humans are not documented, and whether it translates to meaningful drug-level changes at typical supplement doses is unknown. For the detailed pharmacology, see Mushrooms and Cytochrome P450: Do They Affect Drug Metabolism?.

The Interaction Almost No One Covers

Why Reishi and Some Anxiety Drugs Share a Liver Enzyme

CYP3A4 is a liver enzyme that clears a large fraction of prescription drugs. Reishi's triterpenoid compounds can slow it down. If CYP3A4 works more slowly, anxiolytics that depend on it for clearance may accumulate. Lion's mane acts through different pathways and has not been shown to inhibit CYP enzymes.

Reishi (Ganoderma lucidum)

Higher theoretical interaction risk

Mechanism

Triterpenoids inhibit CYP3A4

Concern

Can slow clearance of CYP3A4-substrate benzodiazepines and some SSRIs

In vitro / animal evidence

Lion's Mane (Hericium erinaceus)

Lower theoretical interaction risk

Mechanism

Hericenones / erinacines act on neurotrophic pathways

Concern

No documented inhibition of major CYP enzymes; no dedicated interaction studies

No CYP inhibition documented

The CYP3A4 mechanism comes from in vitro and animal pharmacology. No human clinical interaction cases between reishi and anxiolytics are documented, and whether it produces meaningful drug-level changes at typical supplement doses is unknown. This is a reason for awareness and a clinician conversation, not a proven danger.

Pharmacokinetic mechanism synthesis; interaction unquantified in humans

Lion's mane, by contrast, has not been documented to inhibit major CYP enzymes. Its primary bioactive compounds (hericenones, erinacines) operate through neurotrophic pathways rather than enzyme inhibition, so pharmacokinetic interaction risk appears lower than reishi's, though dedicated drug interaction studies have not been conducted for lion's mane specifically.

The Fijałkowska et al. 2022 review of edible mushrooms for major depressive disorder concluded that the clinical results for reishi are equivocal, that lion's mane shows preliminary positive effects on well-being, and that Cordyceps trials are still underway — a reminder that the human evidence across species is early and uneven rather than settled.^[13]

Safety

Moderate

This is research, not treatment advice

Concern

Anxiety disorders are serious medical conditions. The mushroom trials here are small, mostly short, and several were in non-diagnosed populations. Reishi triterpenoids can inhibit CYP3A4, which metabolizes several benzodiazepines and some SSRIs, so blood levels of those drugs could theoretically rise when reishi is added.

What the research says

Treat functional mushrooms as options to discuss with a clinician, not replacements for prescribed care. Do not stop or reduce a prescribed anxiety medication to try them.

Particularly relevant for: Anyone taking benzodiazepines, SSRIs/SNRIs, or other CYP3A4-metabolized drugs, or who is pregnant or breastfeeding, should consult a clinician before combining them with reishi.

What to do

If you have symptoms of an anxiety disorder, seek professional evaluation; if you have thoughts of self-harm, contact emergency services or a crisis line immediately.

General clinical guidance; Fijałkowska 2022; Cha 2024 review

For more on the interaction profile between functional mushrooms and prescription medications broadly, see Functional Mushrooms for Anxiety: What the Research Shows and Mushrooms for Anxiety Without Psilocybin: Reishi, Lion's Mane, and GABA Research.

The Bottom Line

The most recent controlled trial (Hisamuddin 2026, n=50) found a 33.5% reduction in Hamilton Anxiety scores with a five-mushroom blend vs. 13.1% on placebo over 12 weeks, and a 2021 NHANES analysis found lower adjusted odds of depression in the middle tertile of mushroom intake (OR 0.31), though without a dose-response. Functional mushrooms work through different mechanisms than prescription medications: GABAergic and HPA-axis modulation for reishi, NGF/BDNF induction for lion's mane. Both carry a very different risk profile from pharmaceuticals (no documented dependence risk, rare side effects, no FDA approval). They are not established replacements for prescribed anxiety medications and have a smaller evidence base. Reishi raises a potential pharmacokinetic interaction with CYP3A4-metabolized anxiolytics that warrants attention in people already taking those drugs.

Frequently Asked Questions

Can mushrooms replace anti-anxiety medication?

Functional mushrooms are not FDA-approved for any anxiety disorder and have not been tested in direct head-to-head trials against prescription medications. The strongest available controlled data is Hisamuddin et al.'s 2026 double-blind RCT (n=50), in which a five-mushroom blend cut Hamilton Anxiety scores by 33.5% versus 13.1% on placebo over 12 weeks (p=0.002), with no medication comparison arm.^[1] People currently taking prescribed anxiety medications should not discontinue them based on supplement research. Mushrooms represent a different and less-studied option, not an established equivalent.

What is the difference between adaptogenic mushrooms and benzodiazepines?

Benzodiazepines enhance GABA receptor sensitivity and produce rapid anxiety relief within minutes to hours, but carry a high risk of physical dependence, tolerance, and withdrawal. Adaptogenic mushrooms like reishi work through slower pathways: GABAergic modulation and HPA-axis regulation. Effects develop over weeks, with no documented dependence risk and a favorable safety profile. Benzodiazepines have decades of controlled trial evidence; functional mushrooms have a smaller but growing human research base, most recently a 2026 double-blind RCT showing significant anxiety reductions.^[1]

Are mushroom supplements safe to take with anxiety medications?

The safety question depends on which mushroom and which medication. Reishi triterpenoids inhibit CYP3A4, the liver enzyme that metabolizes several benzodiazepines and some SSRIs. This interaction is documented in in vitro and animal pharmacology, but its clinical significance at supplement doses in humans is not established, and no human interaction cases are on record. People taking CYP3A4-metabolized anxiolytics alongside reishi should be aware of the mechanism and consult a clinician. Lion's mane has not been documented to inhibit major CYP enzymes and may carry lower pharmacokinetic interaction risk.

What natural alternatives exist for anxiety medication?

Within medicinal mushrooms, the strongest evidence is for lion's mane (Nagano 2010 RCT; Vigna 2019, which measured pro-BDNF) and reishi (Mitra 2024 12-week RCT in college students; Pazzi 2020 fibromyalgia data; Hisamuddin 2026 blend trial).^[7][5] These are not FDA-approved alternatives to anxiety medications and their evidence base is smaller. They represent a distinct category of intervention: dietary supplements with a behavioral and neurobiological evidence base, not pharmacological equivalents.

Can you take reishi with antidepressants?

Reishi triterpenoids inhibit CYP3A4 in preclinical models, and some SSRIs and SNRIs are metabolized partly through CYP3A4. Whether this produces clinically meaningful changes in SSRI blood levels at supplement doses has not been studied in humans. The interaction risk is theoretical but mechanistically documented. People taking SSRIs or SNRIs who add reishi to their routine should discuss it with a clinician.

Are functional mushrooms FDA-approved for anxiety?

No functional mushroom species is FDA-approved for treating anxiety disorders. Mushroom supplements are regulated as dietary supplements under the Dietary Supplement Health and Education Act (DSHEA), which does not require demonstrated efficacy before sale and which prohibits disease treatment claims on product labels. Functional mushrooms are legally sold for general wellness purposes, not as treatments for anxiety or any other condition.

Do mushrooms work as well as SSRIs for anxiety?

There are no published head-to-head clinical trials comparing functional mushrooms directly to SSRIs for anxiety. SSRIs have decades of rigorous trial evidence across thousands of patients, including in specifically diagnosed anxiety disorders. The best functional mushroom data currently is the Hisamuddin 2026 double-blind trial (HAM-A anxiety −33.5% vs. −13.1% placebo) and individual RCTs for lion's mane and reishi.^[1] These are not comparable datasets. The mechanisms differ, the populations studied differ, and the scale of the evidence base differs substantially.

Sources & References

1. 1RTHM-00959·Hisamuddin, Ahmad Safiyyu'd-Din et al. (2026). “Adaptogenic Effects of Mushroom Blend Supplementation on Stress, Fatigue, and Sleep: A Randomised, Double-Blind, and Placebo-Controlled Trial..” Brain and behavior.Study breakdown →PubMed →↩
2. 2RTHM-00400·Socala, Katarzyna et al. (2015). “Evaluation of Anticonvulsant, Antidepressant-, and Anxiolytic-like Effects of an Aqueous Extract from Cultured Mycelia of the Lingzhi or Reishi Medicinal Mushroom Ganoderma lucidum (Higher Basidiomycetes) in Mice..” International journal of medicinal mushrooms.Study breakdown →PubMed →↩
3. 3RTHM-00826·Singh, Ranjeet et al. (2016). “Evaluation of Antianxiety Potential of Four Ganoderma (Agaricomycetes) Species from India in Mice..” International journal of medicinal mushrooms.Study breakdown →PubMed →↩
4. 4RTHM-00731·Yao, Chunyan et al. (2021). “Ganoderma lucidum promotes sleep through a gut microbiota-dependent and serotonin-involved pathway in mice..” Scientific reports.Study breakdown →PubMed →↩
5. 5RTHM-00895·Mitra, Sudeep et al. (2024). “Efficacy of Lingzhi or Reishi Medicinal Mushroom Ganoderma lucidum (Agaricomycetes) Supplementation on Psychological Stress and Selective Fitness Profile Parameters in Female College Students in West Bengal, India..” International journal of medicinal mushrooms.Study breakdown →PubMed →↩
6. 6RTHM-00648·Pazzi, Francesco et al. (2020). “Ganoderma lucidum Effects on Mood and Health-Related Quality of Life in Women with Fibromyalgia..” Healthcare (Basel.Study breakdown →PubMed →↩
7. 7RTHM-00194·Nagano, Mayumi et al. (2010). “Reduction of depression and anxiety by 4 weeks Hericium erinaceus intake..” Biomedical research (Tokyo.Study breakdown →PubMed →↩
8. 8RTHM-00590·Vigna, Luisella et al. (2019). “Hericium erinaceus Improves Mood and Sleep Disorders in Patients Affected by Overweight or Obesity: Could Circulating Pro-BDNF and BDNF Be Potential Biomarkers?.” Evidence-based complementary and alternative medicine : eCAM.Study breakdown →PubMed →↩
9. 9RTHM-00952·Surendran, Geyan et al. (2025). “Acute effects of a standardised extract of Hericium erinaceus (Lion's Mane mushroom) on cognition and mood in healthy younger adults: a double-blind randomised placebo-controlled study..” Frontiers in nutrition.Study breakdown →PubMed →↩
10. 10RTHM-00672·Ba, Djibril M et al. (2021). “Mushroom intake and depression: A population-based study using data from the US National Health and Nutrition Examination Survey (NHANES), 2005-2016..” Journal of affective disorders.Study breakdown →PubMed →↩
11. 11RTHM-00868·Cha, Sara et al. (2024). “A review of the effects of mushrooms on mood and neurocognitive health across the lifespan..” Neuroscience and biobehavioral reviews.Study breakdown →PubMed →↩
12. 12RTHM-00943·Menon, Arya et al. (2025). “Benefits, side effects, and uses of Hericium erinaceus as a supplement: a systematic review..” Frontiers in nutrition.Study breakdown →PubMed →↩
13. 13RTHM-01514·Fijałkowska, Agata et al. (2022). “Edible Mushrooms as a Potential Component of Dietary Interventions for Major Depressive Disorder..” Foods (Basel.Study breakdown →PubMed →↩